Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(15 years from now) | |
US11236091 | AMGEN INC | Solid state forms |
May, 2040
(17 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Orphan Drug Exclusivity (ODE) | May 28, 2028 |
NCE-1 date: May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic